For further verification, we could download the mRNA expression data and corresponding clinical information of breast cancer patients from other databases as a validation cohort to verify the relationship between the RSK2 expression level and the clinicopathological features as well as the prognosis of patients. Here, RPS6KA3 is linked to breast carcinoma.